An investment in multiple sclerosis (MS) care and research, and coverage for an important MS drug, was announced by Health Minister Theresa Oswald including setting aside $500,000 for clinical trials of chronic cerebrospinal venous insufficiency (CCSVI) treatment, if and when scientific evidence demonstrates that trials are safe and appropriate.